LT3149480T - B ląstelių pirmtakų ūmia limfoblastine leukemija (all) sergančių pacientų rizikos stratifikacijos būdas - Google Patents

B ląstelių pirmtakų ūmia limfoblastine leukemija (all) sergančių pacientų rizikos stratifikacijos būdas

Info

Publication number
LT3149480T
LT3149480T LTEP15727072.9T LT15727072T LT3149480T LT 3149480 T LT3149480 T LT 3149480T LT 15727072 T LT15727072 T LT 15727072T LT 3149480 T LT3149480 T LT 3149480T
Authority
LT
Lithuania
Prior art keywords
stratification
risk
lymphoblastic leukemia
acute lymphoblastic
leukemia patients
Prior art date
Application number
LTEP15727072.9T
Other languages
English (en)
Inventor
Gerhard Zugmaier
Peter Kufer
Shilpa ALEKAR
Original Assignee
Amgen Research (Munich) Gmbh
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53284315&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3149480(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Research (Munich) Gmbh, Amgen Inc. filed Critical Amgen Research (Munich) Gmbh
Publication of LT3149480T publication Critical patent/LT3149480T/lt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
LTEP15727072.9T 2014-05-30 2015-05-20 B ląstelių pirmtakų ūmia limfoblastine leukemija (all) sergančių pacientų rizikos stratifikacijos būdas LT3149480T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462005560P 2014-05-30 2014-05-30
PCT/IB2015/053705 WO2015181683A1 (en) 2014-05-30 2015-05-20 Risk-stratification of b-precursor acute lymphoblastic leukemia patients

Publications (1)

Publication Number Publication Date
LT3149480T true LT3149480T (lt) 2019-04-25

Family

ID=53284315

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP18213926.1T LT3531133T (lt) 2014-05-30 2015-05-20 Ūminės b pirmtakų limfoblastinės leukemijos pacientų rizikos stratifikacija
LTEP15727072.9T LT3149480T (lt) 2014-05-30 2015-05-20 B ląstelių pirmtakų ūmia limfoblastine leukemija (all) sergančių pacientų rizikos stratifikacijos būdas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP18213926.1T LT3531133T (lt) 2014-05-30 2015-05-20 Ūminės b pirmtakų limfoblastinės leukemijos pacientų rizikos stratifikacija

Country Status (18)

Country Link
US (1) US11079381B2 (lt)
EP (3) EP3149480B1 (lt)
AU (1) AU2015265578B2 (lt)
CA (1) CA2948771C (lt)
CY (2) CY1122600T1 (lt)
DK (2) DK3531133T3 (lt)
ES (2) ES2961565T3 (lt)
FI (1) FI3531133T3 (lt)
HR (1) HRP20231361T1 (lt)
HU (2) HUE063648T2 (lt)
LT (2) LT3531133T (lt)
PL (2) PL3531133T3 (lt)
PT (2) PT3149480T (lt)
RS (1) RS64773B1 (lt)
SI (2) SI3149480T1 (lt)
SM (1) SMT202300383T1 (lt)
TR (1) TR201903548T4 (lt)
WO (1) WO2015181683A1 (lt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
AU2020279224B2 (en) 2019-05-21 2024-12-05 Novartis Ag Trispecific binding molecules against BCMA and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
US8007796B2 (en) 2005-12-16 2011-08-30 Micromet Ag Means and methods for the treatment of tumorous diseases
US20090304657A1 (en) 2006-05-03 2009-12-10 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
WO2008119565A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific binding domain
PL2155788T3 (pl) 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
HUE043326T2 (hu) 2008-11-07 2019-08-28 Amgen Res Munich Gmbh Akut limfoblasztos leukémia kezelése
JP5798036B2 (ja) 2008-11-07 2015-10-21 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 小児急性リンパ芽球性白血病の新規治療
NZ598732A (en) 2009-10-27 2014-09-26 Amgen Res Munich Gmbh Dosage regimen for administering a cd19xcd3 bispecific antibody
ES2806142T3 (es) 2011-04-28 2021-02-16 Amgen Res Munich Gmbh Pauta posológica para administrar un anticuerpo biespecífico CD19xCD3 a pacientes en riesgo de posibles efectos adversos
JO3529B1 (ar) 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد

Also Published As

Publication number Publication date
US11079381B2 (en) 2021-08-03
HUE042407T2 (hu) 2019-06-28
CA2948771C (en) 2023-10-17
LT3531133T (lt) 2023-11-10
WO2015181683A1 (en) 2015-12-03
US20170122947A1 (en) 2017-05-04
WO2015181683A4 (en) 2016-02-04
EP3531133A1 (en) 2019-08-28
PL3531133T3 (pl) 2024-01-29
HUE063648T2 (hu) 2024-01-28
SI3531133T1 (sl) 2023-12-29
SMT202300383T1 (it) 2024-01-10
EP3149480A1 (en) 2017-04-05
HRP20231361T1 (hr) 2024-02-16
SI3149480T1 (sl) 2019-05-31
PT3149480T (pt) 2019-03-21
AU2015265578A1 (en) 2016-11-17
ES2715679T3 (es) 2019-06-05
CA2948771A1 (en) 2015-12-03
TR201903548T4 (tr) 2019-04-22
FI3531133T3 (fi) 2023-11-02
DK3149480T3 (en) 2019-04-01
AU2015265578B2 (en) 2021-09-02
CY1126799T1 (el) 2026-02-25
PT3531133T (pt) 2023-11-07
EP4303585A2 (en) 2024-01-10
EP3531133B1 (en) 2023-08-23
ES2961565T3 (es) 2024-03-12
PL3149480T3 (pl) 2019-06-28
EP4303585A3 (en) 2024-01-24
RS64773B1 (sr) 2023-11-30
CY1122600T1 (el) 2021-03-12
EP3149480B1 (en) 2018-12-26
DK3531133T3 (da) 2023-11-06

Similar Documents

Publication Publication Date Title
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
GB201403093D0 (en) Therapeutic compounds and their use
IL247072A0 (en) Medical use
IL251371A0 (en) Cortexolone 17alpha-benzoate for use in the treatment of tumors
SMT202100115T1 (it) Combinazioni di inibitori di fgfr e cmet per il trattamento del cancro
IL276733A (en) Use of Aribolin in cancer treatment
EP3104880A4 (en) Improved methods for the treatment of vascularizing cancers
IL283335B (en) Dihydropyrimidine-2-one compounds and their medical use
EP3151821A4 (en) Marmelin analogs and methods of use in cancer treatment
EP3175244A4 (en) Compositions for treatment of acute lymphoblastic leukemia and methods of use thereof
EP3145525A4 (en) Use of microperoxidases for the treatment of carboxyhemoglobinemia
EP3110455A4 (en) Treatment of resistant lesions
SI3531133T1 (sl) Stratifikacija tveganj pri bolnikih z akutno limfoblastno levkemijo prekurzorjev b
GB201613350D0 (en) Treatment of hyperpigmentation
AU2014902075A0 (en) New Therapeutic Treatment Combination
EP3212202A4 (en) Use of therapeutic agents
AU2015902062A0 (en) New Therapeutic Treatment Combination
AU2014904330A0 (en) Use of therapeutic agents
EP3116996A4 (en) Treatment of resistant lesions
GB201410387D0 (en) Compounds and their therapeutic use
GB201403496D0 (en) Compounds and their therapeutic use
GB201415302D0 (en) New therapeutic use
HK1232440A1 (en) Improved methods for the treatment of vascularizing cancers